Pfizer Inc
Close on Nov 2, 2026Market cap $174.81BP/E 40.4Yield 5.61%
Pfizer Trazimera [legacy through FY23] by Year
Trazimera (trastuzumab biosimilar) [legacy through FY23] — U.S. revenues ($M) ($M)
Pfizer Trazimera [legacy through FY23]: $8M in FY2023, unchanged from a year earlier. No newer figure appears in the documents we track.
Where the FY2023 figure comes from
“|| Trazimera | 33 | 37 | (11%) | (11%) | 8 | 8 | 6% | 12% | 57 | 51 | 11% | 21%”
Source: Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗
Reported in Form 8-K Revenue Tables & Form 10-Q / 10-K Segment Footnotes.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Trazimera (trastuzumab biosimilar) [legacy through FY23] — U.S. revenues ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2023 | Dec 31, 2023 | 8 | 0.0% | Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗ |
| FY2022 | Dec 31, 2022 | 8 | 0.0% | Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗ |
| FY2021 | Dec 31, 2021 | 8 | +60.0% | Form 8-K (Earnings / Guidance Release) (pfe-12312022xex99.htm, filed 2023-01-31) ↗ |
| FY2020 | Dec 31, 2020 | 5 | – | Form 8-K (Earnings / Guidance Release) (pfe-12312021xex99.htm, filed 2022-02-08) ↗ |
Breakdown
What makes up trazimera [legacy through FY23]
Cite this data
StockData. (2026). Pfizer Trazimera [legacy through FY23] ($M), annual FY2020–FY2023 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/trazimera-leg-us
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.